# A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

> **NCT05741021** · PHASE2 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 84 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- NSCLC
- PD-1

## Interventions

- **DRUG:** F520
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05741021
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2024-10-25
- **Final completion:** 2024-10-25
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741021, "A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05741021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*